Epilepsy

The Worldwide Epilepsy Monitoring Devices Industry is Expected to Reach $615 Million by 2026 - ResearchAndMarkets.com

Thursday, October 21, 2021 - 3:39pm

The global epilepsy monitoring devices market is projected to reach USD 615 million by 2026 from USD 489 million in 2021, at a CAGR of 4.7% during the forecast period.

Key Points: 
  • The global epilepsy monitoring devices market is projected to reach USD 615 million by 2026 from USD 489 million in 2021, at a CAGR of 4.7% during the forecast period.
  • The conventional devices segment accounted for the largest share of the epilepsy monitoring devices market in 2020.
  • Based on products, the epilepsy monitoring devices market has been segmented into wearable devices and conventional devices.
  • North America accounted for the largest share of the epilepsy monitoring devices market in 2020.

EpiWatch, Inc. Announces the Appointment of Michael Singer as Executive Chairman

Thursday, October 21, 2021 - 3:46pm

BALTIMORE, Oct. 21, 2021 /PRNewswire/ --EpiWatch, Inc., a company created by epileptologists at the Johns Hopkins School of Medicine, today announced the appointment of medical device veteran Michael Singer as Executive Chairman.

Key Points: 
  • BALTIMORE, Oct. 21, 2021 /PRNewswire/ --EpiWatch, Inc., a company created by epileptologists at the Johns Hopkins School of Medicine, today announced the appointment of medical device veteran Michael Singer as Executive Chairman.
  • Prior to BrainScope, Singer was President of Revolution Health Investments and has served on several medical device company boards of directors.
  • "There is a tremendous need to provide accessible, patient-friendly digital health tools for people with epilepsy.
  • I could not be more thrilled to join the EpiWatch team to further their mission," said Michael Singer.

Zogenix to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4

Thursday, October 21, 2021 - 1:00pm

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.

Key Points: 
  • Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
  • The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
  • The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.
  • Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

University of Maryland School of Medicine Neurology Chair Peter B. Crino, MD, PhD, Receives Prestigious Neuroscience Award

Thursday, October 21, 2021 - 12:10pm

Senator Javits was a strong advocate for support of research in a wide variety of disorders of the brain and nervous system.

Key Points: 
  • Senator Javits was a strong advocate for support of research in a wide variety of disorders of the brain and nervous system.
  • The Javits Award will greatly augment our lab progress and productivity in these critical areas of research," he said.
  • Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States.
  • The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world.

NeuroPace to Report Third Quarter 2021 Financial Results on November 10, 2021

Wednesday, October 20, 2021 - 9:05pm

MOUNTAIN VIEW, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the third quarter of 2021 after market close on Wednesday, November 10, 2021.

Key Points: 
  • MOUNTAIN VIEW, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the third quarter of 2021 after market close on Wednesday, November 10, 2021.
  • The companys management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.
  • Live audio of the webcast will be available on the Investors section of the companys website at: https://investors.neuropace.com.
  • The webcast will be archived and available for replay for at least 90 days after the event.

Federal judge enters consent decree with Utah-based dietary supplement manufacturer

Wednesday, October 20, 2021 - 8:01pm

SILVER SPRING, Md., Oct. 20, 2021 /PRNewswire/ -- A dietary supplement manufacturer and its two owners have been ordered by a federal court to stop selling products until they come into compliance with federal regulations and requirements under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Key Points: 
  • SILVER SPRING, Md., Oct. 20, 2021 /PRNewswire/ -- A dietary supplement manufacturer and its two owners have been ordered by a federal court to stop selling products until they come into compliance with federal regulations and requirements under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
  • Grandma's Herbs, Inc. manufactured and distributed products, which the company marketed as dietary supplements, with labeling that rendered them unapproved new drugs and misbranded drugs.
  • The consent decree prohibits the defendants from, among other things, directly or indirectly manufacturing or distributing such products until certain requirements are met.
  • "We previously warned this manufacturer, but they continued to make claims that their products could treat or prevent serious diseases.

Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month

Wednesday, October 20, 2021 - 1:00pm

Peete, who has been open about her own familys challenges raising neurodiverse children, is speaking up this October during ADHD Awareness Month to shatter stigmas and encourage those who think their child may have ADHD to learn more and seek treatment.

Key Points: 
  • Peete, who has been open about her own familys challenges raising neurodiverse children, is speaking up this October during ADHD Awareness Month to shatter stigmas and encourage those who think their child may have ADHD to learn more and seek treatment.
  • Before my daughter Ryan was diagnosed with ADHD, I didnt know much about the condition I thought it meant you couldnt keep still, you were fidgety, or were just considered unteachable; but this is not the case, Holly Robinson Peete says.
  • Throughout ADHD Awareness Month and beyond, adults and adolescents alike are encouraged to join the conversation sharing their experiences living with the condition.
  • For more information, visit MoreToADHD.com to sign up to learn more, find resources to help with recognizing, treating, and managing ADHD.

Cerevel Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

Wednesday, October 20, 2021 - 11:30am

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced it will report third quarter 2021 financial results and pipeline updates on Wednesday, November 10, 2021, before the U.S. financial markets open.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced it will report third quarter 2021 financial results and pipeline updates on Wednesday, November 10, 2021, before the U.S. financial markets open.
  • Management will host a conference call to discuss third quarter 2021 financial results and recent pipeline updates on Wednesday, November 10, 2021 at 8:00 a.m.
  • A live webcast of the call, along with supporting slides, will be available on the investors section of Cerevels website here .
  • Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases.

Knopp Biosciences NIH-funded Pain Program Advances to Third Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

Wednesday, October 20, 2021 - 11:00am

Knopp has developed a discovery platform of proprietary molecules directed to a non-opioid biological target linked to chronic pain caused by damage to nerves.

Key Points: 
  • Knopp has developed a discovery platform of proprietary molecules directed to a non-opioid biological target linked to chronic pain caused by damage to nerves.
  • Growing scientific evidence suggests that selectively activating key Kv7 channel subtypes can control nerve-cell hyperexcitability associated with transmission of chronic pain.
  • Receiving this next phase of HEAL funding, based on promising results in preclinical models of chronic and neuropathic pain, positions Knopp to advance our lead drug candidate into IND-enabling studies, said Michael Bozik, M.D., Chief Executive Officer of Knopp.
  • Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need.

NeuroPace Announces Addition of Lisa Andrade to the Board

Tuesday, October 19, 2021 - 9:03pm

MOUNTAIN VIEW, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. , (Nasdaq:NPCE) a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced the addition of Lisa Andrade to its Board of Directors.

Key Points: 
  • MOUNTAIN VIEW, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. , (Nasdaq:NPCE) a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced the addition of Lisa Andrade to its Board of Directors.
  • Lisa Andrade joins NeuroPace with over 25 years of experience in both large and early-stage medtech, software and technology companies.
  • Currently, Ms. Andrade is CEO of M33, an executive coaching and leadership development firm, which she founded in 2018.
  • "I would also like to thank Evan Norton for his service as a board member of NeuroPace.